A5067352004- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Cancer Immunotherapy and Biomarkers
- Bone health and treatments
- Radiopharmaceutical Chemistry and Applications
- Ubiquitin and proteasome pathways
- Radiomics and Machine Learning in Medical Imaging
- Pharmacology and Obesity Treatment
- Immunotherapy and Immune Responses
- Pediatric Pain Management Techniques
- Bone health and osteoporosis research
- Estrogen and related hormone effects
- Genital Health and Disease
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Screening and Detection
- Veterinary Pharmacology and Anesthesia
- Polyamine Metabolism and Applications
- Global Cancer Incidence and Screening
- Theater, Performance, and Music History
- Cancer survivorship and care
- Peptidase Inhibition and Analysis
- Pain Management and Placebo Effect
- Mobile Health and mHealth Applications
- Soft tissue tumors and treatment
Stanford University
2024
Oncology Specialists
2006-2023
VA Sepulveda Ambulatory Care Center
2019
VA Greater Los Angeles Healthcare System
2019
Cedars-Sinai Medical Center
2019
Sinai Health System
2019
Prostate Cancer Research Institute
2016
Cancer Research Institute
2016
University of California, Los Angeles
2005-2012
Prostate Cancer Foundation
2012
Objectives Therapeutic virtual reality (VR) has emerged as an effective, drug-free tool for pain management, but there is a lack of randomized, controlled data evaluating its effectiveness in hospitalized patients. We sought to measure the impact on-demand VR versus "health and wellness" television programming Methods performed prospective, comparative trial patients with average score ≥3 out 10 points. Patients experimental group received library 21 experiences administered using Samsung...
Sipuleucel-T (SIP-T), which functions by stimulating cancer-specific dendritic cells, prolongs survival in men with prostate cancer. Ipilimumab (IPI) achieved a borderline advantage large randomized trial. SIP-T and IPI are potentially synergistic.Nine progressive metastatic castrate-resistant cancer (mCRPC) were treated prospectively followed immediately one of the following doses IPI: 1 mg/kg at week after SIP-T; 4 weeks or 1, 4, 7 SIP-T. Three patients evaluated each level....
The combination of high dose ketoconazole and hydrocortisone (HDK) is active against androgen independent prostate cancer (AIPC). Median response times with HDK tend to be brief but a significant minority AIPC patients benefit extended responses. Well characterized survival information, especially in the cohort who experience these longer, more durable, responses has not been previously reported. Characterization this subgroup particular interest since men long-term derive greatest from...
No AccessJournal of UrologyAdult urology1 May 2006Intermittent Use Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, Henry J. Johnson, Brad W. Guess, and Richard Y. Lam ScholzMark Scholz , JennrichRobert Jennrich StrumStephen Strum JohnsonHenry Johnson GuessBrad Guess LamRichard View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00975-4AboutFull TextPDF ToolsAdd to favoritesDownload...
KRAS G12D mutation has been found in approximately 45% of pancreatic ductal adenocarcinoma (PDAC) cases, making it an attractive therapeutic target. Through structure-based drug design, a series potent and selective inhibitors were designed. The lead compound, ERAS-5024, inhibited ERK1/2 phosphorylation cell proliferation three-dimensional Cell-Titer Glo assays AsPC-1 PDAC cells with single-digit nanomolar potency caused tumor regression the vivo efficacy studies. We describe here details...
368 Background: Phase III trials evaluating enzalutamide or abiraterone in MP-CRPC prior to docetaxel report a median survival of 35 months. SIP-T functions by stimulating cancer-specific dendritic cells and prolongs survival. IPI showed borderline advantage large randomized trial. Thus, there may be potential synergy with (SIPIPI) combination. Methods: Between April 2013 2014, 9 docetaxel-naive men were treated prospectively followed immediately low-dose 1 mg/kg given for total 3 doses...
247 Background: Since FDA approval in 2011, abiraterone (Zytiga) has supplanted docetaxel as preferred first-line treatment for metastatic castrate-resistant prostate cancer. In August 2012 enzalutamide (Xtandi) was FDA-approved the of cancer after (Taxotere). We performed a retrospective chart review at large medical oncology clinic specializing to determine PSA response rates administered men who had previously progressed on both and docetaxel. This report includes some patients...
250 Background: Two previous Phase II trials studying pembrolizumab (Pembro) in 38 patients suggest it may be efficacious for prostate cancer (PC). Methods: Fifty-four consecutive men with recurrent or advanced were treated 1 to 9 cycles of Pembro 200 mg every 3 weeks without SBRT at a private medical oncology clinic specializing PC. Charts retrospectively reviewed response and toxicity. Definitions: Response (R) = >50% PSA decline; Progressive Disease (PD) >50 % increase. Stable (SD)=...
This is the case of a 64-y-old man with metastatic castration-resistant prostate cancer treated 5 cycles 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy. After 2 cycles, prostate-specific levels declined from 26.1 to 15.2 ng/mL (−42%) and interim PSMA PET/CT
A 7-month-old dog presented with a 10-minute history of upper respiratory tract obstruction and secondary loss consciousness in the minute before its arrival to hospital.The was found be dead on arrival.Cardiopulmonary resuscitation initiated, which led successful return spontaneous circulation 20 minutes later, subsequent regain consciousness.Symptomatic therapy supportive care were provided for 3.5 weeks discharging into owners.Despite having made an initial improvement, it subsequently...
Abstract BACKGROUND Active surveillance (AS) is only recommended for Low‐Risk prostate cancer (PC) with <34% biopsies positive. Studies describing the long‐term outcome of men treated androgen deprivation (AD) followed by AS are sparse. MATERIALS AND METHODS One hundred two were 12 months AD in a medical oncology clinic specializing PC between 1998 and 2007 median 7.25 years. The biopsy complete response rate after incidence disease progression while on subsequent was assessed. Baseline...
14531 Background: Prostate cancer has a variable natural history. Researchers and clinicians sorely need marker identifying men destined for early progression to bone metastasis (EPBM). is uniquely sensitive testosterone inactivating pharmaceuticals (TIP) especially when TIP initiated prior the onset of metastasis. Moul 1 reported 10 year median response in with rising PSA after surgery. With such effective therapy, predicting EPBM requires signaling resistance. Elevated nadir likely...
14643 Background: Androgen deprivation therapy (ADT) is a widely administered treatment for prostate cancer. However, ADT associated with accelerated bone loss, osteoporosis, and fractures (Shahinian, NEJM 2005; 352:154). According to Smith et al, annual loss on approaches 9% (Smith, 2001;345:948), using QCT densitometry, highly sensitive test the detection of osteoporosis in men. Intravenous bisphosphonates (pamidronate, zolendronate) have been shown prevent ADT-related randomized phase III...